Access cutting-edge bladder cancer treatment through this clinical trial at a research site in New Haven. Study-provided care at no cost to qualified participants.
Access bladder cancer specialists in New Haven at no cost
This study follows strict safety protocols and ethical guidelines
All study-related bladder cancer treatment provided free
This is a global, multicenter, randomized, open-label study, with an adaptive design. The main objective of the study is to measure the efficacy and safety of BT8009 (zelenectide pevedotin) as monotherapy and in combination with pembrolizumab in participants with locally advanced or metastatic urothelial cancer (UC). The study includes a dose selection phase followed by an adaptive design continuation. The study is comprised of 2 cohorts. Cohort 1 will include participants who have not received
Sponsor: BicycleTx Limited
Check if you qualify for this bladder cancer clinical trial in New Haven, CT
If you're searching for bladder cancer treatment options in New Haven, CT, this clinical trial may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.
Our New Haven research site is actively enrolling participants for this clinical trial. You'll receive care from experienced bladder cancer specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.